Cramer's week ahead: Earnings from Palantir, Berkshire Hathaway, Disney and McDonald's

Jim Cramer provided a selective preview of upcoming earnings reports, emphasizing key narratives for institutional investors. He anticipates strong results from Palantir, citing its recent $10 billion Army contract, and positive performance from Caterpillar due to infrastructure tailwinds. Cramer highlighted the critical need for Pfizer to deliver significant clinical trial outcomes to address shareholder concerns and questioned Eli Lilly's market share dynamics in the GLP-1 sector following Novo Nordisk's recent report. Other focus areas include DuPont's strategic breakup, Berkshire Hathaway's performance under Greg Abel, and Disney's diversified segment growth.

Analysis

The upcoming earnings week presents several distinct narratives for key market players. A highly bullish sentiment surrounds Palantir (PLTR), where expectations are for a 'total blowout' quarter, significantly bolstered by a recent $10 billion U.S. Army contract. Similarly, Caterpillar (CAT) is anticipated to report strong results, driven by secular tailwinds from domestic infrastructure spending and reshoring. In the consumer space, Disney (DIS) is viewed favorably due to climbing share prices and strength across its diversified business segments, while McDonald's (MCD) is presented as a buy on the basis of recent operational improvements. Conversely, significant pressure is mounting on Pfizer (PFE), which requires 'really dramatic' clinical trial results to satisfy an increasingly 'restive' shareholder base, reflecting a negative sentiment score of -0.5. The key focus for Eli Lilly (LLY) will be its competitive standing against Novo Nordisk (NVO); NVO's disappointing quarter raises questions of whether LLY is capturing market share or if the broader GLP-1 drug market is approaching a peak. For special situations, DuPont's (DD) report will be scrutinized for progress on its strategic breakup, a move predicated on the thesis that its component parts are more valuable separately. Meanwhile, Marriott (MAR) presents a tactical challenge, with a history of its stock declining post-earnings even on positive results.

Key Decisions for Investors

• Consider positions in Palantir and Caterpillar, as both are backed by strong positive sentiment and clear fundamental catalysts in government contracts and infrastructure spending, respectively.
• Investors in the pharmaceutical sector should closely watch Eli Lilly's report for evidence of market share capture from Novo Nordisk, while being prepared for significant volatility in Pfizer based on the outcome of its critical clinical trial data.
• Re-evaluate positions in consumer-facing stocks, noting the positive outlook for McDonald's and Disney versus the considerable competitive headwinds facing Wendy's and the potential for a post-earnings pullback in Marriott.
• Monitor DuPont's earnings for explicit updates on its breakup timeline, as the execution of this corporate action is the central pillar of its investment thesis.